Three commonly used molecular drugs including docetaxel, doxorubicin, and gefitinib are used to investigate the effect of TRIM2 expression on the therapeutic sensitivity of lung adenocarcinoma cells. Here, TRIM2 is linked to lung adenocarcinoma.